This inventor holds 1 USPTO granted patent. Top assignee: Dixie Chemical Company. Active years: 2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001
Title: The Innovations of Robert G Brown
Introduction
Robert G Brown is an accomplished inventor based in Houston, TX. He has made significant contributions to the field of chemistry, particularly in the development of pharmaceutical compounds. His work has implications for the treatment of hypertension, showcasing the intersection of innovation and healthcare.
Latest Patents
Robert G Brown holds a patent for "Dinitrile intermediates for the synthesis of omapatrilat and methods for producing same." This patent describes a method for synthesizing omapatrilat, a potent inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Omapatrilat is currently undergoing large-scale clinical trials as an anti-hypertensive medication. The synthesis process involves the use of the S-stereoisomer of a racemic mixture, which can be prepared from a hydantoin. The hydantoin is derived from a novel dinitrile compound, highlighting the innovative approach taken by Brown in his research.
Career Highlights
Robert G Brown is associated with Dixie Chemical Company, where he has been able to apply his expertise in chemical synthesis and pharmaceutical development. His work at the company has allowed him to collaborate with other professionals in the field, further enhancing his contributions to innovation.
Collaborations
One of his notable collaborators is Dwight E Raff, with whom he has worked on various projects related to chemical synthesis and pharmaceutical applications. Their partnership has been instrumental in advancing their research and development efforts.
Conclusion
Robert G Brown's innovative work in the synthesis of pharmaceutical compounds exemplifies the vital role of inventors in advancing healthcare solutions. His contributions continue to impact the field positively, paving the way for future developments in anti-hypertensive treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile